Santhera Pharmaceuticals’ CHF 20 Million Shares Private Placement

Pestalozzi advised H.C. Wainwright on the deal. Homburger advised Santhera.

Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary 
diseases with high unmet medical need listed at SIX Swiss Exchange, announced a CHF 20m private placement.

H.C. Wainwright & Co. is acting as exclusive placement agent for the private placement, consisting of shares and purchase warrants.

The aggregate gross proceeds from the private placement amount to approx. CHF 20m and potential gross proceeds from the purchase warrants amount to CHF 12.5m.

The Pestalozzi team included Christian Leuenberger (Picture – Lead Partner – Capital Markets / M&A), Severin Roelli (Partner – Corporate / M&A) and Monika Maric (Associate – Capital Markets / M&A).

The Homburger team as led by partners Dieter Gericke and Daniel Häusermann (both Capital Markets). Key members of the team included partner Stefan Oesterhelt (Tax), counsel Eduard De Zordi (Capital Markets), associates Margrit Marti, Francesco Bernasconi and Romain Fakhoury (all Capital Markets), as well as junior associate Natalie Pompe.

Involved fees earner: Francesco Bernasconi – Homburger; Eduard De Zordi – Homburger; Romain Fakhoury – Homburger; Dieter Gericke – Homburger; Daniel Häusermann – Homburger; Margrit Marti – Homburger; Stefan Oesterhelt – Homburger; Natalie Pompe – Homburger; Christian Leuenberger – Pestalozzi; Monika Maric – Pestalozzi; Severin Roelli – Pestalozzi;

Law Firms: Homburger; Pestalozzi;

Clients: H.C. Wainwright & Co.; Santhera Pharmaceuticals;

Federica Tiefenthaler

Author: Federica Tiefenthaler